63 research outputs found

    Tunnistatko amiodaronin haittavaikutukset?

    Get PDF
    Amiodaroni on erittäin tehokas, mutta potentiaalisesti toksinen rytmihäiriölääke. Jokaisen potilaita hoitavan lääkärin tulee osata epäillä sen haittavaikutuksia. Niiden hoito ja amiodaronilääkityksen jatkaminen arvioidaan erikoissairaanhoidossa

    Association between Life Stressors and Arterial Stiffness: The Finnish Retirement and Aging Study

    Get PDF
    Objective: Besides traditional risk factors, other factors such as life stressors are linked with incident cardiovascular disease. However, the underlying mechanisms for this association remain mostly unknown. We studied the relation of life stressors (job strain, sleep loss due to worry, illness or death in family, financial difficulties and caregiving) and their accumulation with arterial stiffness, an independent predictor of cardiovascular disease.Methods: 258 participants (mean age 62.4 years, 82% women) from the Finnish Retirement and Aging Study underwent measurements for carotid-femoral Pulse Wave Velocity (PWV), a standard criterion for assessing arterial stiffness and responded to a survey inquiring life stressors. Using analysis of covariance, we estimated group means adjusted for age, gender, occupation, lifestyle factors and hypertension.Results: Participants with recent illness or death in family (8.04 m/s; 95% CI, 7.40-8.73 vs. 7.52 m/s; 95% CI, 7.03-8.05) and financial difficulties (8.65 m/s; 95% CI, 7.62-9.81 vs. 7.71 m/s; 95% CI, 7.21-8.24) had increased PWV compared to those who did not have exposed to these stressors independent of lifestyle factors, diabetes and systolic blood pressure. In addition, increasing number of life stressors demonstrated an association towards increased PWV (>= 2 stressors: 8.04 m/s; 95% CI, 7.42-8.72 vs. 0 stressors 7.74 m/s; 95% CI, 7.23-8.28; p for trend 0.27) but the association attenuated after adjusting for lifestyle factors, diabetes and systolic blood pressure.Conclusion: Life stress was found to associate with higher arterial stiffness. Increased arterial stiffness could explain some of the increased cardiovascular disease risk related to life stressors.HIGHLIGHTS -Arterial stiffness was assesed as carotid-femoral pulse wave velocity.center dot -Illness or death in the family were associated with an increased arterial stiffness.-Financial difficulties were associated with an increased arterial stiffness.-A trend toward increasing number of stressors and higher arterial stiffness exists. (C) 2021 The Authors. Publishing services by Atlantis Press International B.V.</p

    The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF) : study rationale, design, and patient characteristics

    Get PDF
    Atrial fibrillation (AF) is a major cause of ischemic stroke and the number of AF patients is increasing. Thus, up-to-date multifaceted data about the characteristics of AF patients, their treatments, and outcomes are urgently needed. The Finnish anticoagulation in atrial fibrillation (FinACAF) study has collected comprehensive data on all Finnish AF patients from 1st January 2004 to 31st December 2018. The aim of this paper is to describe the study rationale, the process of integrating data from the applied resources and to define the study cohort. Using national unique personal identification number, individual patient data is linked from nationwide health care registries (primary, secondary, and tertiary care), drug purchases, education, and socio-economic status as well as places of domicile, incomes, and taxes. Six regional laboratory databases (similar to 282,000, 77% of the patients) are also included. The study cohort comprises of a total of 411,000 patients. Since the introduction of the national primary care register in 2012, 9% of all AF patients were identified outside hospital care registers. The prevalence of AF in Finland-4.1% of whole population-is for the first time now established. The FinACAF study allows a unique possibility to investigate the epidemiology and socio-medico-economic impact of AF as well as the cost effectiveness of different AF management strategies in a completely unselected, nationwide population. This article provides the rationale and design of the study together with a summary of the characteristics of the cohort.Peer reviewe

    The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics

    Get PDF
    Atrial fibrillation (AF) is a major cause of ischemic stroke and the number of AF patients is increasing. Thus, up-to-date multifaceted data about the characteristics of AF patients, their treatments, and outcomes are urgently needed. The Finnish anticoagulation in atrial fibrillation (FinACAF) study has collected comprehensive data on all Finnish AF patients from 1st January 2004 to 31st December 2018. The aim of this paper is to describe the study rationale, the process of integrating data from the applied resources and to define the study cohort. Using national unique personal identification number, individual patient data is linked from nationwide health care registries (primary, secondary, and tertiary care), drug purchases, education, and socio-economic status as well as places of domicile, incomes, and taxes. Six regional laboratory databases (similar to 282,000, 77% of the patients) are also included. The study cohort comprises of a total of 411,000 patients. Since the introduction of the national primary care register in 2012, 9% of all AF patients were identified outside hospital care registers. The prevalence of AF in Finland-4.1% of whole population-is for the first time now established. The FinACAF study allows a unique possibility to investigate the epidemiology and socio-medico-economic impact of AF as well as the cost effectiveness of different AF management strategies in a completely unselected, nationwide population. This article provides the rationale and design of the study together with a summary of the characteristics of the cohort.</p

    Trajectories of interleukin 10 and heart fatty acid-binding protein levels in traumatic brain injury patients with or without extracranial injuries

    Get PDF
    BackgroundInterleukin 10 (IL-10) and heart fatty acid-binding protein (H-FABP) have gained interest as diagnostic biomarkers of traumatic brain injury (TBI), but factors affecting their blood levels in patients with moderate-to-severe TBI are largely unknown.ObjectiveTo investigate the trajectories of IL-10 and H-FABP between TBI patients with and without extracranial injuries (ECI); to investigate if there is a correlation between the levels of IL-10 and H-FABP with the levels of inflammation/infection markers C-reactive protein (CRP) and leukocytes; and to investigate if there is a correlation between the admission level of H-FABP with admission levels of cardiac injury markers, troponin (TnT), creatine kinase (CK), and creatine kinase MB isoenzyme mass (CK-MBm).Materials and methodsThe admission levels of IL-10, H-FABP, CRP, and leukocytes were measured within 24 h post-TBI and on days 1, 2, 3, and 7 after TBI. The admission levels of TnT, CK, and CK-MBm were measured within 24 h post-TBI.ResultsThere was a significant difference in the concentration of H-FABP between TBI patients with and without ECI on day 0 (48.2 ± 20.5 and 12.4 ± 14.7 ng/ml, p = 0.02, respectively). There was no significant difference in the levels of IL-10 between these groups at any timepoints. There was a statistically significant positive correlation between IL-10 and CRP on days 2 (R = 0.43, p &lt; 0.01) and 7 (R = 0.46, p = 0.03) after injury, and a negative correlation between H-FABP and CRP on day 0 (R = -0.45, p = 0.01). The levels of IL-10 or H-FABP did not correlate with leukocyte counts at any timepoint. The admission levels of H-FABP correlated with CK (R = 0.70, p &lt; 0.001) and CK-MBm (R = 0.61, p &lt; 0.001), but not with TnT.ConclusionInflammatory reactions during the early days after a TBI do not significantly confound the use of IL-10 and H-FABP as TBI biomarkers. Extracranial injuries and cardiac sources may influence the levels of H-FABP in patients with moderate-to-severe TBI

    Trajectories of interleukin 10 and heart fatty acid-binding protein levels in traumatic brain injury patients with or without extracranial injuries

    Get PDF
    Background: Interleukin 10 (IL-10) and heart fatty acid-binding protein (H-FABP) have gained interest as diagnostic biomarkers of traumatic brain injury (TBI), but factors affecting their blood levels in patients with moderate-to-severe TBI are largely unknown. Objective: To investigate the trajectories of IL-10 and H-FABP between TBI patients with and without extracranial injuries (ECI); to investigate if there is a correlation between the levels of IL-10 and H-FABP with the levels of inflammation/infection markers C-reactive protein (CRP) and leukocytes; and to investigate if there is a correlation between the admission level of H-FABP with admission levels of cardiac injury markers, troponin (TnT), creatine kinase (CK), and creatine kinase MB isoenzyme mass (CK-MBm). Materials and methods: The admission levels of IL-10, H-FABP, CRP, and leukocytes were measured within 24 h post-TBI and on days 1, 2, 3, and 7 after TBI. The admission levels of TnT, CK, and CK-MBm were measured within 24 h post-TBI. Results: There was a significant difference in the concentration of H-FABP between TBI patients with and without ECI on day 0 (48.2 ± 20.5 and 12.4 ± 14.7 ng/ml, p = 0.02, respectively). There was no significant difference in the levels of IL-10 between these groups at any timepoints. There was a statistically significant positive correlation between IL-10 and CRP on days 2 (R = 0.43, p < 0.01) and 7 (R = 0.46, p = 0.03) after injury, and a negative correlation between H-FABP and CRP on day 0 (R = -0.45, p = 0.01). The levels of IL-10 or H-FABP did not correlate with leukocyte counts at any timepoint. The admission levels of H-FABP correlated with CK (R = 0.70, p < 0.001) and CK-MBm (R = 0.61, p < 0.001), but not with TnT. Conclusion: Inflammatory reactions during the early days after a TBI do not significantly confound the use of IL-10 and H-FABP as TBI biomarkers. Extracranial injuries and cardiac sources may influence the levels of H-FABP in patients with moderate-to-severe TBI.publishedVersionPeer reviewe

    Association of biallelic RFC1 expansion with early-onset Parkinson's disease

    Get PDF
    Background and Purpose: The biallelic repeat expansion (AAGGG)exp in the replication factor C subunit 1 gene (RFC1) is a frequent cause of cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) as well as late-onset ataxia. The clinical spectrum of RFC1 disease has expanded since the first identification of biallelic (AAGGG)exp and includes now various nonclassical phenotypes. Biallelic (AAGGG)exp in RFC1 in patients with clinically confirmed Parkinson's disease (PD) has recently been found. Methods: A nationwide cohort of 273 Finnish patients with early-onset PD was examined for the biallelic intronic expansion in RFC1. The expansion (AAGGG)exp was first screened using extra long polymerase chain reactions (Extra Large-PCRs) and flanking multiplex PCR. The presence of biallelic (AAGGG)exp was then confirmed by repeat-primed PCR and, finally, the repeat length was determined by long-read sequencing. Results: Three patients were found with the biallelic (AAGGG)exp in RFC1 giving a frequency of 1.10% (0.23%–3.18%; 95% confidence interval). The three patients fulfilled the diagnostic criteria of PD, none of them had ataxia or neuropathy, and only one patient had a mild vestibular dysfunction. The age at onset of PD symptoms was 40–48 years and their disease course had been unremarkable apart from the early onset. Conclusions: Our results suggest that (AAGGG)exp in RFC1 is a rare cause of early-onset PD. Other populations should be examined in order to determine whether our findings are specific to the Finnish population.publishedVersionPeer reviewe

    Eteisvärinäpotilaan liitännäissairaudet rekisteritiedon perusteella

    Get PDF
    Lähtökohdat : Eteisvärinä on merkittävä aivoinfarktin riskitekijä, ja eteisvärinäpotilaan aivoinfarktiriskiin vaikuttavat muun muassa potilaan ikä, sukupuoli ja liitännäissairaudet. Aivoinfarktin riski arvioidaan CHA 2 DS 2 -VASc-pisteytyksen avulla, ja ≥ 2 pistettä saaneella potilaalla riski on suuri. Liitännäissairauksien asianmukainen kirjaaminen potilastietojärjestelmiin sekä terveydenhuollon rekistereihin on tärkeää. Menetelmät : Eteisvärinän aivoinfarktiriskiin vaikuttavien liitännäissairauksien esiintyvyydet ­kerättiin valtakunnallisista terveydenhuollon rekistereistä vuosina 2012–2018 uuden ­eteisvärinädiagnoosin saaneista potilaista (n = 168 356). Tulokset : Verenpainetaudin, hyperkolesterolemian ja diabeteksen suurimmat esiintyvyydet löytyivät lääkeostorekisterin perusteella. Sydämen vajaatoiminta-, valtimosairaus- sekä ­iskeeminen aivohalvaus- ja ohimenevä aivoverenkiertohäiriö (TIA) -diagnooseja tunnistettiin selvästi eniten erikoissairaanhoidon hoitoilmoitusrekisteritiedoista. CHA 2 DS 2 -VASc-arvo ≥ 2 oli miehistä 74,8 %:lla ja naisista 87,1 %:lla. Päätelmät : Kattava analyysi eteisvärinäpotilaiden liitännäissairauksista edellyttää tietojen ­laajamittaista yhdistämistä useista rekisterilähteistä.publishedVersionPeer reviewe
    • …
    corecore